Tykerb / Tyverb (lapatinib) 250 mg film-coated tablets, 70 tablets — original (Novartis, Switzerland) Treatment of adult patients with HER2 (ErbB2)-overexpressing breast cancer: Targeted cancer therapy. Delivery of medications from Europe, cash on delivery +380996042415 WhatsApp

Tykerb / Tyverb / lapatinib

Indications

Treatment of adult patients with HER2 (ErbB2)-positive breast cancer:

 as part of combination therapy with capecitabine for patients with advanced or metastatic breast cancer that has progressed to Previous therapy with trastuzumab in combination with an anthracycline and taxane for metastatic disease;

As part of combination therapy with trastuzumab in patients with metastatic, hormone-negative cancer that has progressed after trastuzumab-containing chemotherapy;

As part of combination therapy with an aromatase inhibitor for postmenopausal women with metastatic, hormone-positive cancer who are not eligible for chemotherapy. Patients in the registration study had not been previously treated with trastuzumab or aromatase inhibitors. There are no data on the efficacy of this combination compared with trastuzumab in combination with an aromatase inhibitor in this patient population.

Dosage and Administration

The course of treatment should only be prescribed by a physician experienced in the use of anticancer drugs.

Before starting treatment, it is necessary to determine the level of the left ventricular ejection fraction to ensure that its initial level is within the established norms (see the section "Special Instructions for Use"). Left ventricular ejection fraction should be monitored during treatment with Tyverb to ensure that it does not decrease below acceptable levels (see "Discontinuation or Dose Reduction" and "Cardiovascular Adverse Reactions").

Tyverb should be taken 1:00 before or 1:00 after meals (see "Pharmacokinetics"). The recommended daily dose of Tyverb should not be divided. To reduce individual patient variability, Tyverb administration should be standardized around mealtimes, for example, always taking the medication one hour before meals.

Missed doses should not be re-taken; the next dose should be continued as scheduled (see Overdose section).

When co-administering with other medications, consult the instructions for use of these medications.

Tyverb in combination with capecitabine.

Recommended dose Tyverb is 1250 mg (5 tablets) once daily.

The recommended dose of capecitabine is 2000 mg/m2/day given in 2 divided doses (every 12:00) each day from days 1 to 14 of a 21-day treatment cycle. It is recommended to take capecitabine with food or within 30 minutes after a meal.

Tyverb in combination with trastuzumab

The recommended dose of Tyverb is 1000 mg (4 tablets) once daily.

The recommended dose of trastuzumab is 4 mg/kg body weight as a loading dose, then 2 mg/kg body weight once weekly.

Tyverb in combination with an aromatase inhibitor.

The recommended dose of Tyverb is 1500 mg (6 tablets) once daily.

The recommended dose of the aromatase inhibitor letrozole is 2.5 mg once daily. When using Tyverb with an alternative aromatase inhibitor, you should read the instructions for use of that drug.